Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FBLG FibroBiologics Inc
- Stocks
- Healthcare
- NASDAQ: FBLG
Price (delayed)
$0.8498
Market cap
$32.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$30.96M
We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple
Highlights
FibroBiologics's EPS has surged by 73% YoY and by 38% QoQ
The net income has surged by 66% year-on-year and by 31% since the previous quarter
The equity has soared by 161% YoY but it fell by 14% QoQ
FBLG's quick ratio has surged by 83% year-on-year but it is down by 3.6% since the previous quarter
Key stats
What are the main financial stats of FBLG
Market
Valuations
Earnings
Shares outstanding
38.26M
Market cap
$32.52M
Enterprise value
$30.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
13.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$14.82M
Net income
-$7.67M
EBIT
-$7.65M
EBITDA
-$7.05M
Free cash flow
-$13.12M
Per share
Balance sheet
Liquidity
EPS
-$0.21
EPS diluted
-$0.21
Free cash flow per share
-$0.36
Book value per share
$0.06
Revenue per share
$0
TBVPS
$0.31
Total assets
$11.43M
Total liabilities
$9.08M
Debt
$7.12M
Equity
$2.35M
Working capital
$1.12M
Debt to equity
3.03
Current ratio
1.14
Quick ratio
1.06
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-64.9%
Return on equity
-564.3%
Return on invested capital
N/A
Return on capital employed
-238%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FBLG stock price
How has the FibroBiologics stock price performed over time
Intraday
7.77%
1 week
9.95%
1 month
-15.86%
1 year
-90.56%
YTD
-57.51%
QTD
-5.58%
Financial performance
How have FibroBiologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$14.82M
Net income
-$7.67M
Gross margin
N/A
Net margin
N/A
The net income has surged by 66% year-on-year and by 31% since the previous quarter
FibroBiologics's operating income has decreased by 47% YoY and by 8% QoQ
Price vs fundamentals
How does FBLG's price correlate with its fundamentals
Growth
What is FibroBiologics's growth rate over time
Valuation
What is FibroBiologics stock price valuation
P/E
N/A
P/B
13.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FibroBiologics's EPS has surged by 73% YoY and by 38% QoQ
The equity has soared by 161% YoY but it fell by 14% QoQ
Efficiency
How efficient is FibroBiologics business performance
The ROA has soared by 64% YoY and by 31% QoQ
FibroBiologics's ROE has decreased by 21% YoY
Dividends
What is FBLG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FBLG.
Financial health
How did FibroBiologics financials performed over time
The total assets is 26% greater than the total liabilities
FBLG's quick ratio has surged by 83% year-on-year but it is down by 3.6% since the previous quarter
FibroBiologics's current ratio has surged by 78% YoY
The equity has soared by 161% YoY but it fell by 14% QoQ
The company's debt fell by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.